With news that leaks in the adult industry that are at least two HIV+ people in the talent pool, we all started to look at ways to reduce the risk of HIV. Scientists can be one step closer when offering a solution.
An injection that has been designed against HIV once a year has successfully completed an important safety study at an early stage, which offers hope for a long -acting alternative to daily pills and bi -monthly injections.
Published in the Lancet Medical Journal, the study showed that Lenacapavir, an antiviral medicine that prevents HIV replication in human cells, remained detectable more than a year after a single dose of trial participants.
If further investigations confirm its effectiveness and safety, Lenacapavir could become the longest durable pre-blot statement prophylaxis (prep) treatment that is available, which significantly reduces the obstacles for HIV prevention.
Currently, PrEP – which reduces the risk of HIV from HIV – requires a daily pill or an injection every two months. Although these methods are very effective, they can be a challenge to maintain over time, especially in risky populations with limited access to health care.
Lenacapavir, an injectable capside inhibitor, works by preventing HIV from replicating within cells. The long duration in the body means that a single annual injection can offer continuous protection – a considerable advantage for people struggling with daily compliance.
In this phase I study, 40 HIV-negative participants received one muscle injection from Lenacapavir, without important side effects. After 56 weeks, researchers confirmed that the medicine remained present in the bloodstream, which indicates the potential effectiveness in the long term.
Researchers emphasized the need for larger and more diverse tests, which will be carried out to further evaluate the effectiveness and safety of the medicine.
The Global HIV challenge and the urge for better prevention
According to 2023 data, about 39.9 million people live with HIV worldwide, with 65% of the cases concentrated in the African region of World Health Organization (WHO).
International organizations, including the WHO, Global Fund and UNAIDS, are committed to terminating the HIV epidemic by 2030, playing a crucial role in this strategy with improved access to PrEP.
HIV activists and medical experts have welcomed the test results, with the emphasis on the game-changing potential of an annual prep injection.
“The prospect of safe annual injectable preparation is just as exciting as transformational,” said Richard Angell of the Terrence Higgins Trust, a leading HIV lustiness.
“We must now prepare for the rollout and finance clinics for sexual health care to do this.”
Despite the promise of new HIV prevention methods, access to existing prep options remains uneven in different regions.
In England, for two months of preparatory injections, the National Institute for Health and Care Excellence (Nice) is still waiting for the National Institute, while Scotland has already approved them.
Prisons, community pharmacists and online health services are still missing consistent access to preparing, leaving many vulnerable populations without crucial protection.
Angell insisted on the health authorities to prioritize fair access to new PrEP methods, so that annual injections, if available, reach all communities in need.
The success of this research at an early stage is a crucial first step towards annual injectable HIV prevention. However, further research is needed to confirm its effectiveness in preventing infection before worldwide health agencies approve widespread use.
If future investigations continue to show strong safety and efficacy, Lenacapavir could mark a new era in HIV prevention, making millions worldwide easier to remain protected with a single annual injection.
If you are an adult artist, don’t forget to check the test of the person you work with. Do not only believe it and only work with artists who test companies that do the antibody test, such as TTS.
If a person refuses to test with TTS (or says they can’t do that), you have to ask yourself why. Are they caught on the fake a test? Or even worse, do they know that their HIV status will be exposed?
Anyway, not worth the risk with someone who cannot or not test with TTS.
For those idiots who say that HIV is not a problem and the medication (art), doctor’s visits and laboratory monitoring (such as CD4 counts and viral loading tests) costs between $ 2,000 and $ 5,000 a month.
Then factor in the side effects, including but not limited to nausea and vomiting, fatigue, diarrhea, headache, rash, weight gain, lipodystrophy, blond density loss, immune reconstitution inflammatory syndrome (iris) and even more serious, kidney and liver damage.
So yes, HIV is a very serious problem. Let nobody tell you otherwise.
Please be careful there and don’t forget to always do your due diligence with everyone with whom you sleep. And more importantly, don’t just assume that someone will be honest with you.
